Jeremy N Rich Selected Research

Growth Factor Receptors

1/2022	PDGF signaling inhibits mitophagy in glioblastoma stem cells through N6-methyladenosine.
1/2019	Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling.
7/2015	Growth Factor Receptor Fusions Predict Therapeutic Sensitivity.
2/2013	Growth factor receptors define cancer hierarchies.
1/2007	Malignant glioma drug discovery - targeting protein kinases.
1/2005	Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeremy N Rich Research Topics

Disease

138	Neoplasms (Cancer) 05/2022 - 05/2002
91	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2004
73	Glioma (Gliomas) 07/2022 - 03/2002
34	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2003
12	Hypoxia (Hypoxemia) 01/2022 - 08/2006
8	Carcinogenesis 12/2020 - 01/2011
4	Ependymoma 11/2020 - 11/2005
3	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2004
3	Leukemia 01/2022 - 07/2018
3	Triple Negative Breast Neoplasms 12/2020 - 12/2013
3	Tics (Tic) 01/2016 - 08/2013
3	Colonic Neoplasms (Colon Cancer) 01/2013 - 04/2004
3	Diarrhea 07/2012 - 01/2004
3	Astrocytoma (Pilocytic Astrocytoma) 01/2008 - 01/2006
2	Meningioma (Meningiomas) 01/2022 - 11/2020
2	Breast Neoplasms (Breast Cancer) 12/2020 - 12/2013
2	Obesity 12/2020 - 12/2013
2	Zika Virus Infection 12/2020 - 01/2020
2	Infections 12/2020 - 02/2009
2	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 12/2013
2	Medulloblastoma 01/2019 - 10/2008
2	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2012 - 05/2008
2	Fatigue 07/2012 - 12/2010

Drug/Important Bio-Agent (IBA)

17	Proteins (Proteins, Gene)FDA Link 05/2022 - 05/2003
13	Phosphotransferases (Kinase)IBA 03/2015 - 12/2004
12	Bevacizumab (Avastin)FDA Link 05/2022 - 08/2006
12	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2015 - 08/2006
11	Temozolomide (Temodar)FDA LinkGeneric 11/2021 - 02/2003
10	Irinotecan (Camptosar)FDA LinkGeneric 12/2011 - 04/2004
8	ChromatinIBA 01/2022 - 05/2015
8	Transcription Factors (Transcription Factor)IBA 11/2019 - 04/2011
8	ErbB Receptors (EGF Receptor)IBA 05/2017 - 01/2004
8	Tyrosine Kinase InhibitorsIBA 07/2012 - 01/2004
7	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2005
7	Monoclonal AntibodiesIBA 11/2008 - 03/2002
6	EnzymesIBA 01/2022 - 02/2006
6	Growth Factor ReceptorsIBA 01/2022 - 01/2005
6	CytokinesIBA 12/2020 - 01/2003
5	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2008
5	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2013
5	Pharmaceutical PreparationsIBA 11/2021 - 01/2007
5	Oxygen (Dioxygen)IBA 11/2020 - 10/2009
5	IntegrinsIBA 01/2020 - 05/2010
5	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 10/2006
4	UbiquitinIBA 01/2022 - 01/2017
4	Histones (Histone)IBA 01/2022 - 12/2015
4	MicroRNAs (MicroRNA)IBA 01/2021 - 07/2014
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018 - 05/2004
4	Imatinib Mesylate (Gleevec)FDA Link 10/2012 - 12/2005
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 03/2012 - 11/2005
4	O(6)-benzylguanineIBA 10/2009 - 05/2002
4	Carmustine (FIVB)FDA Link 08/2009 - 05/2002
3	Methionine (L-Methionine)FDA Link 07/2022 - 05/2017
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2022 - 06/2008
3	Lysine (L-Lysine)FDA Link 01/2022 - 11/2020
3	Biological ProductsIBA 01/2022 - 05/2005
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2022 - 12/2005
3	Tyrosine (L-Tyrosine)FDA Link 11/2021 - 06/2007
3	InterferonsIBA 01/2021 - 01/2020
3	Antiviral Agents (Antivirals)IBA 01/2021 - 01/2020
3	Neutralizing AntibodiesIBA 12/2020 - 08/2006
3	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 10/2013
3	Ligases (Synthetase)IBA 01/2019 - 05/2015
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2015 - 02/2006
3	Hydroxyurea (Hydrea)FDA LinkGeneric 10/2012 - 12/2005
3	LigandsIBA 06/2012 - 06/2004
3	Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA 03/2011 - 08/2008
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 10/2006 - 01/2005
3	Gefitinib (Iressa)FDA Link 02/2006 - 01/2004
3	Transforming Growth Factor beta (TGF-beta)IBA 12/2005 - 01/2003
3	Topoisomerase I InhibitorsIBA 10/2005 - 04/2004
2	N-methyladenosineIBA 01/2022 - 10/2017
2	Deubiquitinating EnzymesIBA 01/2022 - 01/2017
2	Platelet-Derived Growth FactorIBA 01/2022 - 06/2012
2	6-methyladenineIBA 01/2022 - 01/2021
2	ChemokinesIBA 01/2022 - 12/2013
2	Oncogene Proteins (Oncogene Protein)IBA 11/2021 - 07/2014
2	LipidsIBA 01/2021 - 01/2019
2	VaccinesIBA 01/2021 - 12/2020
2	Interferon Type IIBA 01/2020 - 01/2020
2	CateninsIBA 01/2020 - 05/2013
2	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 10/2006
2	NexusIBA 01/2019 - 01/2017
2	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 01/2018 - 05/2014
2	ibrutinibIBA 01/2018 - 11/2017
2	Messenger RNA (mRNA)IBA 10/2017 - 02/2010
2	IronIBA 01/2017 - 10/2015
2	Ferritins (Ferritin)IBA 01/2017 - 10/2015
2	AntibodiesIBA 01/2017 - 01/2013
2	Green Fluorescent ProteinsIBA 07/2015 - 03/2015
2	PeriostinIBA 02/2015 - 04/2004
2	Biomarkers (Surrogate Marker)IBA 07/2014 - 09/2010
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2013 - 07/2011
2	Laminin (Merosin)IBA 11/2012 - 03/2012

Therapy/Procedure

78	Therapeutics 05/2022 - 08/2002
24	Drug Therapy (Chemotherapy) 01/2022 - 01/2004
11	Radiotherapy 04/2015 - 02/2006
4	Immunotherapy 01/2022 - 01/2016
4	Salvage Therapy 03/2012 - 02/2007
2	Transplantation 01/2016 - 06/2011